Lecanemab
Approved · FDA / EMAAlso known as Leqembi.
Recent clinical, regulatory, research and industry developments relating to this drug.
Indication expansion: LECANEMAB-IRMB (BLA761375)
Eisai snares government manufacturing grant as it brings Leqembi packaging to UK with $65M expansion
Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease
Approval: LECANEMAB-IRMB (BLA761375)
Lecanemab: Appropriate Use Recommendations.
Lecanemab in Early Alzheimer's Disease.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Leqembi is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s… Show full indicationShow less
Leqembi is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E 4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology (see section 4.4).
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- The journal of prevention of Alzheimer's disease1
- The New England journal of medicine1
- Aisen P2
- Apostolova L1
- Atri A1
- Bateman RJ1
- Chen C1
- Cohen S1
- Cummings J1
- Dhadda S1
- Yale School of Medicine1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.